Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gt Molecular Inc. is active in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which represents the total active prosecution for this profile. This activity is situated in 1 distinct art unit. The prosecution involves 1 distinct examiner, which means the company's current patenting efforts are focused through a single administrative channel.
GIAMMONA, FRANCESCA FILIPPA is the busiest examiner for the company and is currently handling 1 busiest examiner pending action. This single action is the 1 pending office action identified in the data. With 1 distinct art unit and 1 distinct examiner, the company's current intellectual property outcomes are tied to this specific examination process. Practitioners should note that the prosecution strategy is centralized within the Biotechnology & Pharmaceuticals field under this examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.3% | +58.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18049563 | OFF-TARGET BLOCKING SEQUENCES TO IMPROVE TARGET DISCRIMINATION BY POLYMERASE CHAIN REACTION | GIAMMONA, FRANCESCA FILIPPA | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18049563 | OFF-TARGET BLOCKING SEQUENCES TO IMPROVE TARGET DISCRIMINATION BY POLYMERASE CHAIN REACTION | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGt Molecular Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Francesca Filippa Giammona has the most, with 1 of Gt Molecular Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
